North American Vaccine, Abbott deal

Abbott terminated its 1996 agreement to market NVX's Certiva diphtheria, tetanus and acellular pertussis (DTaP) vaccine to private physicians in the U.S. (see BioCentury, Aug. 19, 1996). The termination will take effect in nine months. NVX will continue selling the vaccine to state and federal government purchasers, and said it is considering options for distributing the vaccine to the private sector. NVX has received the entire $18 million of Certiva-related payments under the $40 million deal, and will not receive any of the remaining $22 million related to combination vaccines covered in the agreement. ...